Pentagastrin: Physiology and What Research Reports

What pentagastrin is

Pentagastrin is a synthetic pentapeptide — a chain of five amino acids — built to mimic the biologically active C-terminal end of the natural human hormone gastrin. Gastrin itself is a larger peptide, but its signalling activity is concentrated in the last few residues of the molecule, which is why a short synthetic fragment can reproduce much of the parent hormone's behaviour. Pentagastrin is not a nutritional or structural peptide; it is a pharmacological probe, historically used to switch on a physiological system deliberately so that the resulting response could be measured.

Its target is the gastrin/cholecystokinin-B receptor, usually written CCK2. That receptor identity is reflected directly in the pharmacology literature: researchers studying the gastrin/CCK2 receptor antagonist netazepide reported dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects, which is consistent with pentagastrin acting through that receptor (PMID 23432534).

Where gastrin biology sits in the body

The hormone pentagastrin imitates is produced by G cells in the antrum of the stomach, with additional expression in parts of the duodenum. Gastrin is released in response to a meal — stomach distension, protein digestion products and vagal input — and travels through the bloodstream back to the stomach wall. There it drives the secretory machinery of the stomach: parietal cells produce hydrochloric acid, and enterochromaffin-like cells release histamine, which amplifies the acid response. Gastrin signalling also has trophic effects on gastric mucosal cell populations, which is why gastrin/CCK2 receptor pharmacology has been of interest well beyond acid physiology.

CCK2 receptors are not confined to the gut. They are also present in the central nervous system, and this dual distribution explains why a single synthetic peptide has been studied by gastroenterologists, endocrine surgeons and psychiatrists for entirely different reasons.

How pentagastrin has been measured and studied

Pentagastrin is generally used as a provocation agent: it is given, and then some downstream variable is measured over time. The measured endpoint differs by field.

Gastric secretion models

Because pentagastrin reliably stimulates the acid-secretory pathway, it has long served as a comparator stimulus in secretion experiments. A veterinary physiology study examined the effect of pyloric blockade together with infusion of histamine or pentagastrin on gastric secretion in horses, using the two secretagogues to characterise the secretory response in that model (PMID 10976748). Work of this kind illustrates the classic use of the peptide: it is the input, not the subject of interest.

Endocrine diagnostic use

Medullary thyroid cancer arises from calcitonin-producing cells, and stimulated calcitonin measurement has been part of its assessment. Researchers evaluated the value of intraoperative pentagastrin testing in medullary thyroid cancer, examining what the stimulated test added in the operative setting (PMID 17263971). This application is a reminder that pentagastrin's clinical footprint has been diagnostic rather than therapeutic, and that availability of the agent has varied by country and era.

Psychiatric challenge paradigms

The central CCK2 receptor population made pentagastrin attractive as an experimental anxiety challenge. One study used the pentagastrin test for anxiety and examined psychophysiology alongside personality measures in the response profile (PMID 12529809). A separate report described pentagastrin-induced sleep panic attacks and reported that panic occurred in the absence of elevated baseline arousal (PMID 12488064), a finding relevant to debates about whether nocturnal panic requires prior physiological activation.

Challenge paradigms also raise the question of whether the response is stable across sessions. Investigators examined the effect of repeat exposure on neuroendocrine and symptom responses to pentagastrin, addressing whether repeated administration changed the magnitude of those responses (PMID 15157745). That design question matters for any within-subject study that plans to use a peptide challenge more than once.

Tolerability and Adverse Events: What Studies Report

Pentagastrin has been used in human research precisely because it produces strong, short-lived effects, and those effects are themselves the reported outcomes. In the psychiatric literature, the study of pentagastrin-induced sleep panic attacks reported that administration provoked panic attacks in the experimental setting (PMID 12488064), and the pentagastrin anxiety-test study reported anxiety symptom and psychophysiological responses that varied with personality measures (PMID 12529809). Researchers also reported on neuroendocrine and symptom responses under repeat exposure conditions (PMID 15157745). In other words, symptom provocation is the documented consequence of the peptide in those protocols, which is why such work was conducted under supervised research conditions. This page does not describe administration practices, and no dosing information is presented here.

Why the term matters to peptide readers

Readers encounter pentagastrin in three fairly different places, and the context changes its meaning entirely:

• Gastrointestinal physiology texts, where it appears as the standard stimulus used to define maximal acid output.
• Endocrine oncology, where stimulated testing has been used in medullary thyroid cancer assessment (PMID 17263971).
• Neuroscience and psychiatry, where it has been used as a panic and anxiety challenge agent (PMID 12488064).

It is also a useful teaching example of a broader principle in peptide science: a short synthetic fragment of a larger hormone can retain receptor activity, and that fragment can then be used either to probe a system or to map it with an antagonist. The netazepide work is a clean illustration, because researchers used pentagastrin responses as the readout against which antagonist blockade was quantified (PMID 23432534).

Limits of the current literature

The published pentagastrin literature is largely made up of small mechanistic and diagnostic studies across different species and specialties, rather than large outcome trials. Findings from a veterinary secretion model (PMID 10976748) do not transfer directly to human physiology, and psychiatric challenge findings describe provoked laboratory states rather than long-term clinical courses (PMID 12529809). Availability of pentagastrin as a diagnostic product has also changed over time in several regions, which is one reason stimulated testing protocols differ between centres and eras.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, symptom, diagnosis or treatment decision. Nothing here describes how any substance should be obtained or administered.

References

• Pentagastrin test for anxiety—psychophysiology and personality (Psychopharmacology, 2003)
• Effect of pyloric blockade and infusion of histamine or pentagastrin on gastric secretion in horses (American Journal of Veterinary Research, 2000)
• The value of intraoperative pentagastrin testing in medullary thyroid cancer (Surgery, 2007)
• Effect of repeat exposure on neuroendocrine and symptom responses to pentagastrin (Psychiatry Research, 2004)
• Pentagastrin-induced sleep panic attacks: panic in the absence of elevated baseline arousal (Biological Psychiatry, 2002)
• Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects (British Journal of Clinical Pharmacology, 2013)